Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols
Reuben Ben‐David, Neeraja Tillu, Parissa Alerasool, Christine Bieber, Daniel Ranti, Serena Tolani, Justin Eisenhauer, Rainjade Chung, Étienne Lavallée, Nikhil Waingankar, Kyrollis Attalla, Peter Wiklund, Reza Mehrazin, Christopher B. Anderson, John P. Sfakianos
Topics & Concepts
MedicineDocetaxelGemcitabineBladder cancerInternal medicineInduction chemotherapyUrologyNephrologyRetrospective cohort studyMaintenance therapyOncologyChemotherapyCancerSurgeryBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCholangiocarcinoma and Gallbladder Cancer Studies